Delivery Order SPE2DB20D1100-SPE2DB25FC7Z2
Award Date
6/9/25
Potential Completion Date
7/1/25
Potential Value
$120K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $24,038.58 firm fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product. The contract has an ultimate completion date of May 6, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, which provides a...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $48,077.16 and a period of performance through May 14, 2025. The contract provides for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. This contract is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an award value of $60,096.40 and is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a medical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical division. This IDC serves as...
This federal contract award, with a ceiling value of $24,038.58, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product, with a period of performance through June 4, 2025. The contract is a Delivery Order and is Firm Fixed Price. The award is not set-aside and was an open competition. Amerisourcebergen Drug...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $47,834.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a completion date of January 8, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $119,585.40 and a completion date of December 26, 2024. This is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $61,154.69 delivery order contract is for the medical product OCREVUS 300 MG/10 ML VIAL 10ML, with a performance period through April 7, 2025. The contract is a firm fixed-price type, with no set-aside designation. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $180,289.20 firm fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract has an ultimate completion date of June 4, 2025. This award is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This federal contract award, valued at $120,192.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order (SPE2DB20D1100|SPE2DB25FC0E8) for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract is a firm fixed-price arrangement with a period of performance through May 20, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC)...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $24,038.58 delivery order contract is for the provision of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract is a Firm Fixed Price agreement, with an ultimate completion date of June 20, 2025. Amerisourcebergen Drug Corp is the prime contractor for this award, which is not designated as a set-aside contract. The company also holds a...